We’ve discussed metformin here and here. And in my book, Radical Resilience, I had this to say.

“”Metformin is being studied in a large-scale clinical trial called Targeting Aging by Metformin (TAME)… It regulates mTOR and Sirtuins, leads to lower IGF-1, and activates AMPK. The results of the TAME study should offer more guidance on the safety and efficacy of this medication in countering aging. (longevity)

“”Medications can easily tip us into Dr. Three territory… So let other people be the final guinea pigs. Remember, we want to follow the Dr. One approach harnessing the body’s own systems with lifestyle changes and acupuncture.”

YouTube video here with a brief discussion

Main thesis for Longevity and Metformin

• The idea that metformin is a broad “longevity drug” or “geroprotector” has become popular, but the highest-quality evidence does not support this.
• Early observational studies appeared very promising, but many suffered from serious statistical biases.
• As better randomized controlled trials (RCTs) have accumulated, most of the exciting claims have failed to hold up.

Why researchers became excited about longevity

• Diabetic patients taking metformin appeared to:
  • live longer than diabetics on other medications.
  • in one famous study, even outlive healthy non-diabetics.
• If true, this would suggest metformin slows aging itself.
• Unfortunately, later analyses found that healthier patients were preferentially prescribed metformin, creating misleading results. Once these biases were corrected, the longevity advantage largely disappeared.

Cancer prevention for Longevity: disappointing results

The article reviews years of cancer research.

Large randomized trials found:

• no improvement in overall survival
• no reduction in cancer progression
• no convincing reduction in cancer recurrence

This includes:

• prostate cancer
• breast cancer
• ovarian cancer
• digestive cancers

A large Canadian study (MAST) specifically examined men with low-risk prostate cancer undergoing active surveillance.

Result:

• virtually identical cancer progression in metformin and placebo groups.
• no meaningful benefit.

One subgroup analysis even suggested obese men did slightly worse on metformin, although this may simply represent statistical chance.

Meta-analyses of Cancer reduction for Longevity

Several meta-analyses including thousands of patients concluded:

• no improvement in cancer-free survival
• no improvement in overall survival
• no convincing reduction in new cancer development

These findings greatly weaken the hypothesis that metformin is a general anti-cancer drug.

Possible exceptions

The article does identify several areas that remain interesting.

Small randomized trials suggest metformin might help:

• reduce recurrence of colorectal adenomas (precancerous colon polyps)
• possibly improve treatment of endometrial hyperplasia
• possibly reduce endometrial thickening in women taking tamoxifen

However:

• these studies are relatively small.
• results need replication.
• they do not justify broad preventive use in healthy adults.

Important downside

The author emphasizes one concern that longevity researchers increasingly discuss:

Several studies suggest metformin blunts some of the beneficial adaptations to exercise, including improvements in:

• mitochondrial function
• insulin sensitivity
• muscle adaptation

Since exercise remains one of the strongest proven longevity interventions, this potential tradeoff is important.

---

Main takeaways

• Evidence strongly supports metformin for Type 2 diabetes.
• Evidence does not currently support metformin as a general anti-aging drug.
• Early observational studies were probably misleading because of selection bias.
• Large randomized trials have generally failed to show meaningful longevity or cancer benefits.
• There may be a role in a few narrowly defined high-risk conditions (especially colorectal adenoma prevention), but this remains an active area of research.
• Healthy people should not assume metformin prevents cancer or extends lifespan.
• Metformin may interfere with some exercise-induced adaptations, which is an important consideration for healthy adults focused on longevity.
• The article argues that longevity medicine should move away from searching for a single “magic pill” and instead demand evidence for specific drugs in specific populations for specific outcomes.

Is there any basis for taking metformin if you don’t have Type 2 diabetes?

Based on the evidence reviewed in this article—and I think this is a fair reflection of the broader literature as of mid-2026—the answer is:

For most healthy people: probably not.

There are a few situations where metformin is evidence-based or reasonably considered outside of Type 2 diabetes, including:

• Prediabetes, especially in people at high risk of progressing to diabetes (supported by long-term prevention studies).
• Polycystic ovary syndrome, where it can improve insulin resistance and ovulation.
• Some cases of antipsychotic-induced weight gain or insulin resistance.
• Selected research settings involving colorectal adenoma prevention or endometrial disease, though these are not established longevity indications.

For healthy, metabolically normal adults taking metformin solely to live longer, the evidence remains unconvincing. In fact, the possibility that it dampens some of the benefits of exercise makes the risk-benefit calculation less favorable than many people assumed a decade ago.

Given your interest in longevity science and in translating evidence for the public, I’d say the current scientific message is becoming much more nuanced: exercise, sleep, diet, maintaining a healthy weight, blood pressure control, and avoiding smoking still have vastly stronger evidence for extending healthspan than metformin does. That makes for a valuable story because it highlights the difference between an intriguing hypothesis and an intervention that has actually been proven to improve healthy aging.

Keys MT, Thinggaard M, Larsen LA, Pedersen DA, Hallas J, Christensen K. Reassessing the evidence of a survival advantage in Type 2 diabetes treated with metformin compared with controls without diabetes: a retrospective cohort study. Int J Epidemiol. 2022 Dec 13;51(6):1886-1898. doi: 10.1093/ije/dyac200. PMID: 36287641.

Bannister, C.A., Holden, S.E., Jenkins-Jones, S., Morgan, C.L., Halcox, J.P., Schernthaner, G., Mukherjee, J. and Currie, C.J. (2014), Can people with type 2 diabetes live longer than those without? A comparison of mortality in people initiated with metformin or sulphonylurea monotherapy and matched, non-diabetic controls. Diabetes Obes Metab, 16: 1165-1173. https://doi.org/10.1111/dom.12354